Hyeyeong Kim

1.1k total citations
28 papers, 478 citations indexed

About

Hyeyeong Kim is a scholar working on Oncology, Hepatology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Hyeyeong Kim has authored 28 papers receiving a total of 478 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 13 papers in Hepatology and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Hyeyeong Kim's work include Hepatocellular Carcinoma Treatment and Prognosis (13 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Hyeyeong Kim is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (13 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Hyeyeong Kim collaborates with scholars based in South Korea, Switzerland and China. Hyeyeong Kim's co-authors include Jaekyung Cheon, Beodeul Kang, Hong Jae Chon, Jinhyang Choi, Jin Seong Lee, Jung Shin Lee, Si Yeol Song, Joohee Jung, Eun Jin Ju and Jaesook Park and has published in prestigious journals such as Journal of Clinical Oncology, Biomaterials and Journal of Hepatology.

In The Last Decade

Hyeyeong Kim

27 papers receiving 467 citations

Peers

Hyeyeong Kim

HEPAT

ONCOL

IMMUN

Song Yi Baek South Korea

Ke Ge China

Yufeng Yuan China

Gangshi Wang China

Yadi Li United States

Mehmet Haluk Morgül Germany

Chikara Shirata Japan

Roxan F.C.P. Helderman Netherlands

Sung Yeun Yang South Korea

Masato Imamura Japan

Song Yi Baek South Korea

Hyeyeong Kim

69 ×0.4

HEPAT

51 ×0.3

ONCOL

40 ×0.3

64 ×0.7

IMMUN

80 ×1.1

Citations per year, relative to Hyeyeong Kim Hyeyeong Kim (= 1×) peers Song Yi Baek

Countries citing papers authored by Hyeyeong Kim

Since Specialization

Citations

This map shows the geographic impact of Hyeyeong Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hyeyeong Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hyeyeong Kim more than expected).

Fields of papers citing papers by Hyeyeong Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hyeyeong Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hyeyeong Kim. The network helps show where Hyeyeong Kim may publish in the future.

Co-authorship network of co-authors of Hyeyeong Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Hyeyeong Kim. A scholar is included among the top collaborators of Hyeyeong Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hyeyeong Kim. Hyeyeong Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kim, Hyung‐Don, Sun Jin Sym, Hong Jae Chon, et al.. (2025). Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab. Journal of Hepatology. 84(2). 308–315. 3 indexed citations

Kim, Jung Sun, Beodeul Kang, Il Hwan Kim, et al.. (2024). Distinct Characteristics and Changes in Liver Function of Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab for More Than 1 Year. Cancer Research and Treatment. 56(4). 1231–1239. 2 indexed citations

Chan, Stephen L., Baek‐Yeol Ryoo, Frankie Mo, et al.. (2024). Multicentre phase II trial of cabozantinib in patients with hepatocellular carcinoma after immune checkpoint inhibitor treatment. Journal of Hepatology. 81(2). 258–264. 24 indexed citations

Lee, Jinhyung, et al.. (2024). Do hospital data breaches affect health information technology investment?. Digital Health. 10. 589867876–589867876. 3 indexed citations

Kim, Hyeyeong, et al.. (2024). Effectiveness of self-reported management program of cancer patients. Digital Health. 10. 599896802–599896802. 1 indexed citations

Kim, Hyeyeong, Hyeon-Su Im, Jae‐Cheol Jo, et al.. (2023). Catastrophizing Maladaptive Coping Affects the Association Between Viral Anxiety and Fear of Progression in Cancer Patients During COVID-19 Pandemic. Psychiatry Investigation. 20(12). 1204–1210. 2 indexed citations

Yang, Hannah, Beodeul Kang, Yeonjung Ha, et al.. (2023). High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma. JHEP Reports. 5(4). 100672–100672. 48 indexed citations

Kim, Hyeyeong, et al.. (2023). Development and pilot study of “Smart Cancer Care”: a platform for managing side effects of chemotherapy. BMC Health Services Research. 23(1). 922–922. 6 indexed citations

Chan, Stephen L., Baek‐Yeol Ryoo, Frankie Mo, et al.. (2023). A phase II clinical trial to study the use of cabozantinib (cabo) in patients with hepatocellular carcinoma (HCC) post immunotherapy treatment.. Journal of Clinical Oncology. 41(4_suppl). 571–571. 3 indexed citations

10.

Song, Young Shin, Hannah Yang, Beodeul Kang, et al.. (2023). Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma. Liver Cancer. 13(1). 89–98. 12 indexed citations

11.

Kim, Hyeyeong, et al.. (2022). The Validation Study of the Stress and Anxiety to Viral Epidemics−6 Scale Among Patients With Cancer in the COVID-19 Pandemic. Frontiers in Psychiatry. 13. 811083–811083. 4 indexed citations

12.

Noh, Eui‐Kyu, Yoo Jin Lee, Youjin Kim, et al.. (2022). The soluble VCAM-1 level is a potential biomarker predicting severe acute graft versus host disease after allogeneic hematopoietic cell transplantation. BMC Cancer. 22(1). 997–997. 2 indexed citations

13.

Koh, Su‐Jin, Kyung‐Ah Kang, Hyeyeong Kim, et al.. (2022). Perceptions of the meaning of life among Korean patients with advanced cancer: A mixed-methods study. Palliative & Supportive Care. 21(4). 658–669. 9 indexed citations

14.

Chon, Young Eun, Jaekyung Cheon, Hyeyeong Kim, et al.. (2022). Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment. Cancer Medicine. 12(3). 2731–2738. 26 indexed citations

15.

Cheon, Jaekyung, et al.. (2022). Organ-specific responses to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma.. Journal of Clinical Oncology. 40(16_suppl). 4076–4076. 3 indexed citations

16.

Kim, Hyeyeong, et al.. (2022). Sophisticated 3D microstructural reconstruction for numerical analysis of electrolyte imbibition in Li-ion battery separator and anode. Materials Science and Engineering B. 284. 115878–115878. 5 indexed citations

17.

Kim, Hyeyeong, Jaekyung Cheon, Han Sang Kim, et al.. (2022). Atezolizumab plus bevacizumab in Child-Pugh B advanced hepatocellular carcinoma patients.. Journal of Clinical Oncology. 40(4_suppl). 397–397. 3 indexed citations

18.

Kim, Hyeyeong, Hyeon-Su Im, Young Joo Min, et al.. (2021). Changes in decision-making process for life-sustaining treatment in patients with advanced cancer after the life-sustaining treatment decisions-making act. BMC Palliative Care. 20(1). 63–63. 11 indexed citations

19.

Choi, Su Jin, et al.. (2019). Infliximab-Induced Lupus in Crohn’s Disease. Korean Journal of Medicine. 94(3). 303–307.

20.

Choi, Jinhyang, Hyeyeong Kim, Eun Jin Ju, et al.. (2012). Use of macrophages to deliver therapeutic and imaging contrast agents to tumors. Biomaterials. 33(16). 4195–4203. 190 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact